The dilemma of resuming anticoagulation after intracranial hemorrhage little evidence facing big fears

Stroke

Volumn 42, Issue 12, 2011, Pages 3665-3666

  Molina, Carlos A ^a   Selim, Magdy H ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Acute stroke; Hemorrah; Intracranial stenosis

Indexed keywords

DABIGATRAN; WARFARIN;

ANTICOAGULATION; BRAIN HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SURVIVAL RATE; THROMBOEMBOLISM; VASCULAR AMYLOIDOSIS;

ANTICOAGULANTS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; DRUG ADMINISTRATION SCHEDULE; HUMANS; RISK; STROKE;

EID: 84856226709     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.631689     Document Type: Note

References (2)

1. De Vleeschouwer S, Van Calenbergh F, van Loon J, Nuttin B, Goffin J, Plets C. Risk analysis of thromboembolic and recurrent bleeding events in the management of intracranial hemorrhage due to oral anticoagulation. Arch Chir Belg. 2005;105:268-274. (Pubitemid 40905552)
2. Classen DO, Kazemi N, Zubkov AY, Wijdicks EF, Rabinstein AA. Restarting anticoagulation therapy after warfarin-associated intracranial hemorrhage. Arch Neurol. 2008;65:1313-1318.